News blog

Cyprotex

• BY: Andrew Hore |
• POSTED: 20/09/2012 |

Cyprotex has launched CellCiphr Premier, which it claims is one of the most reliable clinical predictors of potential drug toxicity on the market.

Cyprotex offers pharma companies services that enable them to choose the compounds most likely to be effective.

A delayed contract hit US revenues in the first half of 2012. European revenues were one-fifth higher but overall revenues were 5% ahead at £3.72m. A small profit was turned into a £222,000 loss. The business is second half weighted so Cyprotex is still on course to make a full year profit.

The reliance on larger customers is reducing with the largest customer 13% of revenues. Even though the US has been disappointing additional capacity is being installed.

Net debt was £579,000 at the end of June. Cyprotex has been investing in new equipment but there should be a significant cash inflow later in the year.

At 4.88p a share, Cyprotex is valued at £10.9m.

Download the latest AIM Journal from http://www.hubinvest.com/AIMPDFSeptember2012_36.pdf